Presentation is loading. Please wait.

Presentation is loading. Please wait.

The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé.

Published bySudirman Darmadi Modified over 5 years ago

Similar presentations

Presentation on theme: "The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé."— Presentation transcript:

1 The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé EverfLex NitInol STent SYstem II (DURABILITY II)  Jon S. Matsumura, MD, Dai Yamanouchi, MD, PhD, Jeffrey A. Goldstein, MD, Christopher W. Pollock, MD, Marc Bosiers, MD, Greg A. Schultz, MD, Dierk Scheinert, MD, Krishna J. Rocha-Singh, MD  Journal of Vascular Surgery  Volume 58, Issue 1, Pages e1 (July 2013) DOI: /j.jvs Copyright © 2013 Society for Vascular Surgery Terms and Conditions

2 Fig 1 A, Protégé EverFlex Self-Expanding Peripheral Stent cut in an open lattice design showing spiral cell connectors, three-wave peaks, peak-to-peak connection nodes, and tantalum markers at the proximal and distal ends of the stent; available in stent lengths of 20, 30, 40, 60, 80, 100, 120, 150, and 200 mm. B, A 200-mm stent is depicted. Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2013 Society for Vascular Surgery Terms and Conditions

3 Fig 2 Kaplan-Meier estimate of freedom from loss of primary patency defined as peak systolic velocity (PSV) ratio <2.0 and no clinically driven reintervention within the stented segment. # At Risk gives the number of patients at risk of an event at the start of the interval, whereas # Censored and # Events are the incremental counts of patients censored or with events during the interval. CI, Confidence interval. Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2013 Society for Vascular Surgery Terms and Conditions

4 Fig 3 Kaplan-Meier estimate of freedom from loss of assisted primary patency defined as peak systolic velocity (PSV) ratio <2.0 maintained by repeated percutaneous intervention completed before complete vessel occlusion. # At Risk gives the number of patients at risk of an event at the start of the interval, whereas # Censored and # Events are the incremental counts of patients censored or with events during the interval. CI, Confidence interval. Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2013 Society for Vascular Surgery Terms and Conditions

5 Fig 4 Kaplan-Meier estimates of freedom from loss of secondary patency. Secondary patency was defined as peak systolic velocity (PSV) ratio <2.0 maintained by repeat percutaneous intervention after occlusion of the target lesion. # At Risk gives the number of patients at risk of an event at the start of the interval, whereas # Censored and # Events are the incremental counts of patients censored or with events during the interval. CI, Confidence interval. Journal of Vascular Surgery  , e1DOI: ( /j.jvs ) Copyright © 2013 Society for Vascular Surgery Terms and Conditions

Download ppt "The United States StuDy for EvalUating EndovasculaR TreAtments of Lesions in the Superficial Femoral Artery and Proximal Popliteal By usIng the Protégé."

Similar presentations

Superficial Femoral Artery Recanalization with Self-expanding Nitinol Stents: Long-term Follow-up Results  M. Ferreira, L. Lanziotti, M. Monteiro, G.

Superficial Femoral Artery Recanalization with Self-expanding Nitinol Stents: Long-term Follow-up Results  M. Ferreira, L. Lanziotti, M. Monteiro, G.
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.

Predictors of restenosis in the use of helical interwoven nitinol stents to treat femoropopliteal occlusive disease  Yiu Che Chan, MBBS, MD, FRCS, Stephen.
Revised duplex criteria and outcomes for renal stents and stent grafts following endovascular repair of juxtarenal and thoracoabdominal aneurysms  Walid.

Revised duplex criteria and outcomes for renal stents and stent grafts following endovascular repair of juxtarenal and thoracoabdominal aneurysms  Walid.
Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease  Gustavo S. Oderich, MD, Luke.

Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease  Gustavo S. Oderich, MD, Luke.
Freedom from secondary interventions to treat stenotic disease after percutaneous transluminal angioplasty of infrarenal aorta: long-term results  J.P.P.M.

Freedom from secondary interventions to treat stenotic disease after percutaneous transluminal angioplasty of infrarenal aorta: long-term results  J.P.P.M.
Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions  Tomoharu Dohi,

Incidence, predictors, and prognosis of in-stent occlusion after endovascular treatment with nitinol stents for femoropopliteal lesions  Tomoharu Dohi,
Stenting of femoropopliteal lesions using interwoven nitinol stents

Stenting of femoropopliteal lesions using interwoven nitinol stents
First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease  Johannes Lammer, MD, Marc.

First clinical trial of nitinol self-expanding everolimus-eluting stent implantation for peripheral arterial occlusive disease  Johannes Lammer, MD, Marc.
A percutaneous arterial closure protocol can decrease complications after endovascular interventions in vascular surgery patients  Philip P. Goodney,

A percutaneous arterial closure protocol can decrease complications after endovascular interventions in vascular surgery patients  Philip P. Goodney,
Endovascular treatment of long lesions of the superficial femoral artery: Results from a multicenter registry of a spiral, covered polytetrafluoroethylene.

Endovascular treatment of long lesions of the superficial femoral artery: Results from a multicenter registry of a spiral, covered polytetrafluoroethylene.
Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions  Andrew M. Bakken, MD, Eugene Palchik, MD, Joseph P. Hart,

Impact of diabetes mellitus on outcomes of superficial femoral artery endoluminal interventions  Andrew M. Bakken, MD, Eugene Palchik, MD, Joseph P. Hart,
Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices 

Clinical significance of embolic events in patients undergoing endovascular femoropopliteal interventions with or without embolic protection devices 
Adjunctive use of the superficial femoral vein for vascular reconstructions  Soma Brahmanandam, MD, MPH, Daniel Clair, MD, James Bena, MS, Timur Sarac,

Adjunctive use of the superficial femoral vein for vascular reconstructions  Soma Brahmanandam, MD, MPH, Daniel Clair, MD, James Bena, MS, Timur Sarac,
Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions  Takao Ohki, MD, PhD, Kimihiko.

Outcomes of the Japanese multicenter Viabahn trial of endovascular stent grafting for superficial femoral artery lesions  Takao Ohki, MD, PhD, Kimihiko.
A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous.

A randomized phase II study of Xilonix, a targeted therapy against interleukin 1α, for the prevention of superficial femoral artery restenosis after percutaneous.
Results of the United States multicenter prospective study evaluating the Zenith fenestrated endovascular graft for treatment of juxtarenal abdominal.

Results of the United States multicenter prospective study evaluating the Zenith fenestrated endovascular graft for treatment of juxtarenal abdominal.
Arne Gerhard Schwindt, MD, Giuseppe Panuccio, MD, Konstantinos P

Arne Gerhard Schwindt, MD, Giuseppe Panuccio, MD, Konstantinos P
Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)  William R. Hiatt,

Long-term safety of cilostazol in patients with peripheral artery disease: The CASTLE study (Cilostazol: A Study in Long-term Effects)  William R. Hiatt,

Similar presentations

Ads by Google